Three quotes:
"When it comes to anti-clotting medications, there is no free lunch," said Deepak Bhatt, cardiologist and professor of medicine at the Cleveland Clinic.
The TRITON trial , Bhatt writes, “may have spawned an antithrombotic version of Scylla and Charybdis for the clinician on a quest to suppress important ischemic events while trying to steer clear of major bleeding complications, including potentially fatal ones.”
"This is going to be a very troubling finding with the FDA," said Gordon Tomaselli, a professor of medicine at Johns Hopkins Medicine. "I suspect they'll need more trials to address this."
No comments:
Post a Comment